hERG Channel Inhibitors in Extracts of Coptidis Rhizoma

Abstract

Inhibition of the hERG channel delays repolarization and prolongs the QT interval and cardiac action potential which can lead to sudden death. Several drugs have been withdrawn from the market due to hERG channel inhibition. In the search of hERG channel inhibitors of natural origin, we established an HPLC-based profiling approach which combines HPLC-microfractionation and bioactivity testing on Xenopus laevis oocytes. The methanolic extract of the TCM herbal drug Coptidis rhizoma (Coptis chinensis Franch., Ranunculaceae) reduced the peak tail hERG current by 31.7 ± 2.0 % at 100 µg/mL. HPLC-based activity profiling pointed towards berberine as the active constituent. However, hERG inhibition by 100 µM of a reference sample of berberine (16.3 ± 1.6 %) was less pronounced than previously reported. Subsequent LC‐PDA‐MS analysis showed that berberine collected by microfractionation of the Coptis extract had been, in part, transformed to active dihydroberberine. Formic acid added to the HPLC mobile phase to reduce peak tailing of protoberberine alkaloids acted as a reducing reagent according to the mechanism of the Leuckart-Wallach reaction. Among other structurally related protoberberines tested, dihydroberberine (30.1 ± 10.1 % at 100 µM) was the most potent hERG inhibitor.

Key words

hERG channel inhibition - herbal extracts - Coptis chinensis - Ranunculaceae - HPLC‐based activity profiling - protoberberine alkaloids

References

• 1 Hancox J C, McPate M J, El Harchi A, Zhang Y H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.  Pharmacol Therapeut. 2008;  119 118-132
• 2 Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development.  Pharmacol Res. 2008;  57 181-195
• 3 Deisemann H, Ahrens N, Schlobohm I, Kirchhoff C, Netzer R, Möller C. Effects of common antitussive drugs on the hERG potassium channel current.  J Cardiovasc Pharm. 2008;  52 494-499
• 4 Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.  J Appl Toxicol. 2009;  29 183-206
• 5 Scholz E P, Zitron E, Kiesecker C, Lück S, Thomas D, Kathöfer S, Kreye V A W, Katus H A, Kiehn J, Schoels W, Karle C A. Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.  Naunyn Schmiedebergs Arch Pharmacol. 2005;  371 516-525
• 6 Lin C R, Ke X G, Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition.  Cardiology. 2008;  110 145-152
• 7 Zitron E, Scholz E, Owen R W, Lück S, Kiesecker C, Thomas D, Kathöfer S, Niroomand F, Kiehn J, Kreye V A W, Katus H A, Schoels W, Karle C A. QTc prolongation by grapefruit juice and its potential pharmacological basis – HERG channel blockade by flavonoids.  Circulation. 2005;  111 835-838
• 8 Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes for drug screening.  Pflugers Arch Eur J Physiol. 2006;  453 117-123
• 9 Kim H J, Baburin I, Khom S, Hering S, Hamburger M. HPLC-based activity profiling approach for the discovery of GABA(A) receptor ligands using an automated two microelectrode voltage clamp assay on Xenopus oocytes.  Planta Med. 2008;  74 521-526
• 10 Zaugg J, Baburin I, Strommer B, Kim H J, Hering S, Hamburger M. HPLC-based activity profiling: discovery of piperine as a positive GABA(A) receptor modulator targeting a benzodiazepine-independent binding site.  J Nat Prod. 2010;  73 185-191
• 11 Stöger E A, Friedl F. Arzneibuch der Chinesischen Medizin, German edition. Stuttgart; Deutscher Apotheker Verlag 2009
• 12 Tang W, Eisenbrand G. Chinese drugs of plant origin. Berlin; Springer-Verlag 1992: 361-371
• 13 Ma B L, Ma Y M, Shi R, Wang T M, Zhang N, Wang C H, Yang Y. Identification of the toxic constituents in Rhizoma Coptidis.  J Ethnopharmacol. 2010;  128 357-364
• 14 Kong W J, Zhao Y L, Xiao X H, Jin C, Li Z L. Quantitative and chemical fingerprint analysis for quality control of rhizoma Coptidis chinensis based on UPLC-PAD combined with chemometrics methods.  Phytomedicine. 2009;  16 950-959
• 15 Ernst E. Harmless herbs? A review of the recent literature.  Am J Med. 1998;  104 170-178
• 16 Potterat O, Hamburger M. Natural products in drug discovery – Concepts and approaches for tracking bioactivity.  Curr Org Chem. 2006;  10 899-920
• 17 Stork D, Timin E N, Berjukow S, Huber C, Hohaus A, Auer M, Hering S. State dependent dissociation of HERG channel inhibitors.  Br J Pharmacol. 2007;  151 1368-1376
• 18 Rodriguez-Menchaca A, Ferrer-Villada T, Lara J, Fernandez D, Navarro-Polanco R A, Sanchez-Chapula J A. Block of hERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels.  J Cardiovasc Pharm. 2006;  47 21-29
• 19 Li B X, Yang B F, Zhou J, Xu C Q, Li Y R. Inhibitory effects of berberine on I-K1, I-K, and HERG channels of cardiac myocytes.  Acta Pharmacol Sin. 2001;  22 125-131
• 20 Brewer A R E. Leuckart-Wallach reaction. Li JJ, Corey EJ Name reactions of functional group transformations. Hoboken, New Jersey; John Wiley & Sons, Inc. 2007: 451-455
• 21 Lukasiewicz A. A study of the mechanism of certain chemical reactions—I: The mechanism of the leuckart-wallach reaction and of the reduction of schiff bases by formic acid.  Tetrahedron. 1963;  19 1789-1799
• 22 Kondo Y, Imai J, Inoue H. Reaction of protoberberine-type alkaloids. Part 12: a facile method for regiospecific oxygenation and excited oxidative ring-cleavage of berberine alkaloids.  J Chem Soc [Perkin I]. 1980;  911-918
• 23 Wang Y X, Zheng Y M. Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine.  J Cardiovasc Pharm. 1997;  30 214-222
• 24 Bensky D, Clavey S, Stöger E. Chinese herbal medicine – materia medica, 3rd edition. Seattle; Eastland Press, Inc. 2004: 134-138
• 25 Turner N, Li J Y, Gosby A, To S W C, Cheng Z, Miyoshi H, Taketo M M, Cooney G J, Kraegen E W, James D E, Hu L H, Li J, Ye J M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I – A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.  Diabetes. 2008;  57 1414-1418
• 26 Ye M Z, Fu S, Pi R B, He F. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research.  J Pharm Pharmacol. 2009;  61 831-837
• 27 Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry.  Drug Metab Dispos. 2006;  34 2064-2072
• 28 Hua W Y, Ding L, Chen Y, Gong B, He J C, Xu G L. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.  J Pharm Biomed Anal. 2007;  44 931-937
• 29 Yang Y H, Kang N, Xia H J, Li J, Chen L X, Qiu F. Metabolites of protoberberine alkaloids in human urine following oral administration of coptidis Rhizoma decoction.  Planta Med. 2010;  76 1859-1863
• 30 Qiu F, Zhu Z Y, Kang N, Piao S J, Qin G Y, Yao X S. Isolation and identification of urinary metabolites of berberine in rats and humans.  Drug Metab Dispos. 2008;  36 2159-2165
• 31 Tsai P L, Tsai T H. Hepatobiliary excretion of berberine.  Drug Metab Dispos. 2004;  32 405-412
• 32 Cheng Z, Chen A F, Wu F, Sheng L, Zhang H K, Gu M, Li Y Y, Zhang L N, Hu L H, Li J Y, Li J. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.  Bioorg Med Chem. 2010;  18 5915-5924

1 The authors contributed equally to this work.